Alex Matika
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alex Matika has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Esrat Jahan
Department of Pharmacy, St. Luke’s University Health Network, Bethlehem, USA
1 shared publication - Justin Miller
Department of Pharmacy, St. Luke’s University Health Network, Bethlehem, USA
1 shared publication - Lauren Allen
Department of Pharmacy, St. Luke’s University Health Network, Bethlehem, USA
1 shared publication
Latest Publications
- 27 August 2026
- Published by Springer Nature in Infection
- Vol. 54 (5) , 2663-2670
Oral transition therapy versus intravenous therapy for the treatment of uncomplicated Enterococcal bloodstream infections
Purpose Growing evidence supports oral transition therapy for gram-negative and certain Staphylococcus bloodstream infections (BSIs). However, clinical data remains limited for other organisms. The purpose of this study is to assess whether oral transition therapy is non-inferior to intravenous (IV)-only therapy for uncomplicated Enterococcal BSIs. Methods This single-center, retrospective, non-inferiority, observational study included adult patients with microbiology-confirmed Enterococcus bacteremia who received appropriate definitive antibiotic therapy. The primary composite outcome was treatment failure, defined as recurrence of BSI, development of deep-seated infection, or all-cause mortality within 90 days. Secondary outcomes included the individual components of the composite outcome, readmission within 90 days related to the index infection, hospital length of stay, and treatment-emergent adverse events. Results Of the 156 included patients, 123 received IV-only therapy, and 33 were transitioned to oral therapy. Treatment failure occurred in 18% (22/123) of patients in the IV-only group and 12% (4/33) in the oral group (RR 0.68, 95% CI 0.25–1.83), with a similar safety profile observed in both groups. Additionally, the hospital length of stay was significantly shorter in the oral group (6 vs. 8 days, p < 0.01). Conclusion Given this study was underpowered, a statistical non-inferiority could not be established. However, given a numerically lower rate of treatment failure observed in the oral therapy group without any overt safety concern, oral transition therapy may be considered in clinically stable patients with uncomplicated Enterococcal BSIs.
- 27 August 2026
- Published by Springer Nature in Infection
- Vol. 54 (5) , 2663-2670
Oral transition therapy versus intravenous therapy for the treatment of uncomplicated Enterococcal bloodstream infections
Purpose Growing evidence supports oral transition therapy for gram-negative and certain Staphylococcus bloodstream infections (BSIs). However, clinical data remains limited for other organisms. The purpose of this study is to assess whether oral transition therapy is non-inferior to intravenous (IV)-only therapy for uncomplicated Enterococcal BSIs. Methods This single-center, retrospective, non-inferiority, observational study included adult patients with microbiology-confirmed Enterococcus bacteremia who received appropriate definitive antibiotic therapy. The primary composite outcome was treatment failure, defined as recurrence of BSI, development of deep-seated infection, or all-cause mortality within 90 days. Secondary outcomes included the individual components of the composite outcome, readmission within 90 days related to the index infection, hospital length of stay, and treatment-emergent adverse events. Results Of the 156 included patients, 123 received IV-only therapy, and 33 were transitioned to oral therapy. Treatment failure occurred in 18% (22/123) of patients in the IV-only group and 12% (4/33) in the oral group (RR 0.68, 95% CI 0.25–1.83), with a similar safety profile observed in both groups. Additionally, the hospital length of stay was significantly shorter in the oral group (6 vs. 8 days, p < 0.01). Conclusion Given this study was underpowered, a statistical non-inferiority could not be established. However, given a numerically lower rate of treatment failure observed in the oral therapy group without any overt safety concern, oral transition therapy may be considered in clinically stable patients with uncomplicated Enterococcal BSIs.